There is no way that ACW can be cashed up till late 2025 without existing unlisted options being exercised. This is also a reason as to why a pullback/retracement will occur as well. They still need a sizeable amount of cash to fund the remaining AZ non Australian trial extension which is after the projected interim analysis mid 2025.
This what I posted. Read the first line!
Ann: Positive Xanamem biomarker trial published in Jnl Alz Dis, page-74
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
